The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 21, 2021
Filed:
Aug. 05, 2016
Applicant:
Dana-farber Cancer Institute, Inc., Boston, MA (US);
Inventors:
Assignee:
Dana-Farber Cancer Institute, Inc., Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C07H 21/04 (2006.01); A61P 35/02 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01); C12Q 1/6886 (2018.01); C12Q 1/6883 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61P 35/02 (2018.01); C12Q 1/6883 (2013.01); G01N 33/5011 (2013.01); G01N 33/5038 (2013.01); G01N 33/5044 (2013.01); G01N 33/574 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/154 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2570/00 (2013.01); G01N 2800/22 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01); G01N 2800/60 (2013.01); G01N 2800/7028 (2013.01);
Abstract
Provided herein are non-invasive methods and biomarkers that identify progression and clonal evolution of plasma cell dyscrasias. Also provided are materials and methods for the diagnosis, prognosis, staging, and monitoring of plasma cell dyscrasias based on the presence of the bio markers in a blood biopsy, as well as methods for monitoring the progression of a plasma cell dyscrasia, determining the efficacy of a therapeutic agent, determining a targeted therapy related to a plasma cell dyscrasia, and/or treating a plasma cell dyscrasia. The methods provided herein provide several advantages over invasive biopsies.